Fairvalue-Calculator Fairvalue-Calculator
EN DE

Almeda Ventures Limited (AMDA) Fair Value & Analysis

Healthcare · Il · Market cap 51.8M ILA

Price2.60 ILA
Fair Value1.67 ILA
Upside-35.7%
Quality95/100
Evidence: Medium Range 1.25 ILA – 2.08 ILA

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Almeda Ventures Limited (AMDA) currently trades at 2.60 ILA, while our model-based Fair Value estimate is 1.67 ILA — implying the stock looks roughly 35.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Almeda Ventures Limited Partnership is a venture capital firm specializing in seed, start up, early venture and middle market investments. The firm seeks to invest in health technology with focus on public R&D partnership, medical devices, digital health and bio-convergence; life sciences research and development company. It prefers to invest in Israel, USA and Europe. Almeda Ventures Limited Partnership was founded in 2020 and is based in Tel Aviv, Israel.

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) +20% Pro Medicus Limited (PME) -81% BrightSpring Health Services, Inc (BTSG) -61% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -6% M3, Inc (MTHRY) +43%

Frequently asked questions

Is Almeda Ventures Limited (AMDA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1.67 ILA versus a price of 2.60 ILA — about −36% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AMDA?
Our 21-model fair value for Almeda Ventures Limited is 1.67 ILA (as of Jun 24, 2026), built from audited fundamentals. The current price is 2.60 ILA.
What is the quality score of AMDA?
Almeda Ventures Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.